^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Chronic Lymphocytic Leukemia
    Regimen: (cyclophosphamide + fludarabine IV + Rituxan (rituximab))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Jpn J Clin Oncol
    Title:

    A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia

    Published date:
    11/27/2020
    Excerpt:
    We investigated the efficacy and safety of FCR in this single-arm, multicenter study designed as a bridging study to the CLL8 study by the German CLL Study Group....Although the number of patients was limited, FCR appears to be effective with manageable toxicity for treatment-naïve fit Japanese patients with CD20-positive CLL.
    DOI:
    10.1093/jjco/hyaa215